COST-EFFECTIVENESS OF BOCEPREVIR THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C (HCV) GENOTYPE 1

被引：1
|
作者：
Mernagh, P. [1 ]
Feng, J. [1 ]
Del Cuore, M. [2 ]
机构：
[1] Optum, Sydney, NSW, Australia
[2] Merck Sharp & Dohme Australia, Sydney, NSW, Australia
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.440
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A94 / A94
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Enea, Marco
    Bruno, Raffaele
    Bronte, Fabrizio
    Capursi, Vincenza
    Cicchetti, Americo
    Colombo, Giorgio L.
    Di Marco, Vito
    Gasbarrini, Antonio
    Craxi, Antonio
    [J]. HEPATOLOGY, 2012, 56 (03) : 850 - 860
  • [2] COST-EFFECTIVENESS OF BOCEPREVIR IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN SWEDEN
    Chhatwal, J.
    Lundberg, J.
    Ferrante, S.
    El Khourhy, A. C.
    Oksanen, A.
    Elbasha, E. H.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S386 - S387
  • [3] Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Cabibbo, Giuseppe
    Ruggeri, Matteo
    Enea, Marco
    Bruno, Raffaele
    Capursi, Vincenza
    Gasbarrini, Antonio
    Alberti, Alfredo
    Craxi, Antonio
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 658 - 666
  • [4] Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
    Petta, Salvatore
    Cabibbo, Giuseppe
    Enea, Marco
    Macaluso, Fabio Salvatore
    Plaia, Antonella
    Bruno, Raffaele
    Gasbarrini, Antonio
    Bruno, Savino
    Craxi, Antonio
    Camma, Calogero
    [J]. DIGESTIVE AND LIVER DISEASE, 2014, 46 (10) : 936 - 942
  • [5] COST-EFFECTIVENESS OF BOCEPREVIR BASED REGIMENS IN PREVIOUSLY UNTREATED ADULT SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE 1
    Ferrante, Shannon A.
    Chhatwal, Jagpreet
    Elbasha, Elamin
    Dasbach, Erik J.
    El Khoury, Antoine
    Poordad, F. Fred
    Bronowicki, Jean-Pierre
    Brass, Clifford A.
    [J]. HEPATOLOGY, 2011, 54 : 795A - 796A
  • [6] Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States
    Chhatwal, Jagpreet
    Ferrante, Shannon A.
    Brass, Cliff
    El Khoury, Antoine C.
    Burroughs, Margaret
    Bacon, Bruce
    Esteban-Mur, Rafael
    Elbasha, Elamin H.
    [J]. VALUE IN HEALTH, 2013, 16 (06) : 973 - 986
  • [7] Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal
    Elbasha E.H.
    Chhatwal J.
    Ferrante S.A.
    El Khoury A.C.
    Laires P.A.
    [J]. Applied Health Economics and Health Policy, 2013, 11 (1) : 65 - 78
  • [8] The cost-effectiveness of boceprevir for hepatitis C
    Neoh, Chin Fen
    Kong, David C. M.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (03) : 319 - 334
  • [9] COST-EFFECTIVENESS OF BOCEPREVIR ADD-ON TREATMENT OF HEPATITIS C VIRUS GENOTYPE 1 PATIENTS IN DENMARK
    Ehlers, L.
    Ferrante, S.
    Kristensen, M. H.
    Leutscher, P. D. C.
    Chhatwal, J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A354 - A354
  • [10] COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ARGENTINA
    Garcia Marti, S.
    Alcaraz, A.
    Valanzasca, P.
    Garay Ulises, U.
    McMullen, M.
    Rey Ares, L.
    Peirano, I
    Bessone, F.
    Fainboim, H.
    Gadano, A.
    Galdame, O.
    Vujacich, C.
    Caporale, J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A692 - A692
12345